Dopa-Responsive Dystonia - The Story so Far

Abstract

Dopa-responsive dystonia (DRD) is an eminently treatable condition and its recognition is therefore of crucial importance. In classical cases, the disease manifests in early childhood with walking problems due to dystonia of the lower limbs. The dystonia is frequently accompanied by “parkinsonian” features such as reduced facial expression or slowing of fine finger movements. Biochemically, the disorder is typically characterized by low levels of the neurotransmitter metabolite homovanillic acid and reduced levels of neopterin and tetrahydrobiopterin (BH4) in the cerebrospinal fluid. This is due to heterozygote mutations of the GTP cyclohydrolase I gene, which is the rate-limiting enzyme in the synthesis of BH4. BH4 is an essential co-factor for tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of dopamine. Reduced levels of BH4 lead to the dopamine-deficit syndrome DRD because of reduced TH activity. Other genes implicated in the pathogenesis of this disorder are the TH gene itself and the parkin gene. This article summarizes all relevant aspects of DRD including recent advances in the genetics of this disorder and the widening phenotype. Particular emphasis is given to clinically relevant aspects such as diagnostic difficulties and atypical presentations in infancy and early childhood.

Key words

Dopa-Responsive Dystonia - GTP Cyclohydrolase I - L-Dopa - Tyrosine Hydroxylase - Tetrahydrobiopterin

References

• 1 Bandmann O, Daniel S, Marsden C D, Wood N W, Harding A E. The GTP cyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study.  J Neurol Sci. 1996;  141 27-32
• 2 Bandmann O, Nygaard T, Surtees R AH, Marsden C D, Wood N W, Harding A E. Dopa-responsive dystonia in British patients: new mutations of the GTP cyclohydrolase I gene and evidence for genetic heterogeneity.  Hum Mol Genet. 1996;  5 403-406
• 3 Bandmann O, Marsden C D, Wood N W. Atypical presentations of dopa-responsive dystonia.  Adv Neurol. 1998;  78 283-290
• 4 Bandmann O, Valente E M, Holmans P, Surtees R AH, Walters J H, Wevers R A. et al . A clinical and genetic study of dopa-responsive dystonia.  Ann Neurol. 1998;  44 649-656
• 5 Bezin L, Nygaard T G, Neville J D, Shen H, Levin R A. Reduced lymphoblast neopterin detects GTP cyclohydrolase dysfunction in dopa-responsive dystonia.  Neurology. 1998;  50 1021-1027
• 6 Fink J, Barton N, Cohen W, Lovenberg W, Burns R, Hallett M. Dystonia with marked diurnal variation associated with biopterin deficiency.  Neurology. 1988;  38 707-711
• 7 Furukawa Y, Lang A E, Trugman J M, Bird T D, Hunter A, Sadeh M. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia.  Neurology. 1998;  50 1015-1020
• 8 Furukawa Y, Guttman M, Sparagana S P, Trugman J M, Hyland K, Rouleau G A. et al . Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene.  Ann Neurol. 2000;  47 517-520
• 9 Furukawa Y, Graf W D, Wong H, Shimadzu M, Kish S J. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations.  Neurology. 2000;  56 260-263
• 10 Hwu W-L, Chiou Y-W, Lai S-Y, Lee Y-M. Dopa-responsive dystonia is induced by a dominant-negative mechanism.  Ann Neurol. 2000;  48 609-613
• 11 Hufton S, Jennings I, Cotton R. Structure and function of the aromatic amino acid hydoxylases.  Biochem J. 1995;  311 353-366
• 12 Hyland K, Fryburg J S, Wilson W G, Bebin E M, Arnold L A, Gunaskera R S. et al . Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test.  Neurology. 1997;  48 1290-1297
• 13 Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M. et al . Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.  Nature Genet. 1994;  8 236-242
• 14 Ichinose H, Suzuki T, Inagaki H, Ohye T, Nagatsu T. Molecular genetics of dopa-responsive dystonia.  Biol Chem. 1999;  380 1355-1364
• 15 Jarman P, Bandmann O, Marsden C D, Wood N W. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs.  J Neurol Neurosurg Psychiatry. 1997;  63 304-308
• 16 Knappskog P, Flatmark T, Mallet J, Luedecke B, Bartholome K. Recessively inherited L-dopa-responsive dystonia caused by a point mutation (381 K) in the tyrosine hydroxylase gene.  Hum Mol Genet. 1995;  4 1209-1212
• 17 LeWitt P, Miller L, Levine R, Lovenberg W, Newman R, Papavasiliou A. et al . Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trial.  Neurology. 1986;  36 760-764
• 18 Luedecke B, Dworniczak B, Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome.  Hum Mut. 1995;  95 123-125
• 19 Luedecke B, Knappskog P, Clayton P, Surtees R, Clelland J, Heales S. et al . Recessively inherited L-dopa-responsive parkinsonism in infancy caused by a point mutation (L205 P) in the tyrosine hydroxylase gene.  Hum Mol Genet. 1996;  5 1023-1028
• 20 Montagna P, Procaccianti G, Lugaresi A, Zuconi M, Lugaresi E. Diurnal variability in cranial dystonia.  Mov Disord. 1990;  5 44-46
• 21 Nichol C, Smith G, Duch O. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin.  Ann Rev Biochem. 1995;  54 729-764
• 22 Nygaard T, Marsden C D, Duvoisin R. Dopa-responsive dystonia.  Adv Neurol. 1988;  50 377-384
• 23 Nygaard T, Trugman J, Yebenes J, Marsden C D. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family.  Neurology. 1990;  40 66-69
• 24 Nygaard T, Marsden C D, Fahn S. Dopa-responsive dystonia: long term treatment response and prognosis.  Neurology. 1991;  41 174-181
• 25 Nygaard T, Takahashi H, Heiman G, Snow B, Fahn S, Calne D. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.  Ann Neurol. 1992;  32 603-608
• 26 Nygaard T. Dopa-responsive dystonia.  Adv Neurol. 1993;  60 577-585
• 27 Nygaard T G, Wilhelmsen K C, Risch N J, Brown D L, Trugman J M, Gilliam T C. et al . Linkage mapping of dopa-responsive dystonia (DRD) to chromosome 14 q.  Nature Genet. 1993;  5 386-390
• 28 Nygaard T, Waran S, Levine R, Naini A, Chutorian A. Dopa-responsive dystonia simulating cerebral palsy.  Pediatr Neurol. 1994;  11 236-240
• 29 O'Sullivan J D, Costa D C, Gacinovic S, Lees A J. SPECT imaging of the dopamine transporter in juvenile-onset dystonia.  Neurology. 2001;  56 266-267
• 30 Ouvrier R. Progressive dystonia with marked diurnal fluctuation.  Ann Neurol. 1978;  4 412-417
• 31 Rajput A, Gibb W, Zhong X, Shannak K, Kish S, Chang L. et al . Dopa-responsive dystonia: pathological and biochemical observations in a case.  Ann Neurol. 1994;  35 396-402
• 32 Rijk-van Andel J F, Gabreëls F JM, Geurtz B, Steenbergen-Spanjers G CH, van den Heuvel L PWJ, Smeitink J AM. et al . L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency.  Neurology. 2000;  55 1926-1928
• 33 Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation.  Adv Neurol. 1976;  14 215-233
• 34 Steinberger D, Weber Y, Korinthenberg R, Deuschl G, Benecke R, Martinius J. et al . High penetrance and pronounced variation in expressivity of GCH1 mutations in five families with dopa-responsive dystonia.  Ann Neurol. 1998;  43 634-639
• 35 Tassin J, Dürr A, Bonnet A-M, Gil R, Vidailhet M, Lücking C B. et al . Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations?.  Brain. 2000;  123 1112-1121
• 36 Williams A, Eldridge R, Levine R, Lovenberg W, Paulson G. Low CSF hydroxylase cofactor (tetrahydrobiopterin) levels in inherited dystonia.  Lancet. 1979;  2 410-411
• 37 Williams A, Levine R, Chase T, Lovenberg W, Calne C. CSF hydroxylase cofactor levels in some neurological diseases.  J Neurol Neurosurg Psychiatry. 1980;  43 735-738